^
    Back
    Association details:
    Biomarker:MCM4 overexpression
    Cancer:Liposarcoma
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Cell Dev Biol
    Title:

    MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma

    Published date:
    06/10/2021
    Excerpt:
    ...we comprehensively analyzed the expression profiles of 100 liposarcomas...MCM4 overexpression tumors were therapeutically sensitive to PARP inhibitor (PARPi) and platinum chemotherapy, independent of the histology subtypes. Our study, for the first time, suggested that MCM4 might be a novel prognostic biomarker, associated with dysregulated DNA repair pathways and potential therapeutic vulnerability in STS.
    DOI:
    https://doi.org/10.3389/fcell.2021.666376